New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
07:59 EDTROSGRosetta Genomics platform predicts bladder cancer progression in published study
Rosetta Genomics announces the publication of clinical data in an article entitled, "The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer." The study profiled and analyzed microRNA expression levels in 86 samples of non-muscle-invasive bladder cancer to identify patterns of expression that are indicative of a high probability of disease progression. The main finding showed that in the least invasive tumors, low expression levels of miR-10a are correlated to later recurrence of the disease in a more invasive form. According to study author, Ulrika Segersten, Ph.D., Department of Surgical Sciences, Uppsala University, Uppsala, Sweden, "Profiling revealed that certain microRNAs predicted the risk of developing higher stage among patients with Ta cancers. Lower miR-10a-5p expression in Ta progressing tumors indicates that this microRNA could have a crucial role for later invasion of non-invasive bladder tumors."
News For ROSG From The Last 14 Days
Check below for free stories on ROSG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
08:41 EDTROSGRosetta Genomics announces Alzheimer's agreement with global pharma company
Subscribe for More Information
July 29, 2014
08:47 EDTROSGRosetta Genomics announces research collaboration with Weizmann Institute
Rosetta Genomics announces that the company has entered into a collaborative research and license agreement with Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science. The agreement involves collaboration with the Nancy and Stephen Grand Israel National Center for Personalized Medicine to develop novel methods for the preparation of next-generation sequencing libraries for small RNAs. The initial goals of this collaboration are to make this type of sequencing more cost effective as well as to minimize sequence-specific biases. The collaboration also aims at developing computational methods required for data analysis. The potential developed methods could allow more accurate quantification of microRNAs in various biological samples and pathological conditions.
July 22, 2014
09:31 EDTROSGRosetta Genomics receives final NY approval for its kidney cancer test
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use